{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE345nnn/GSE345409/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE345409"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"CD39-stratified CD8+ tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma profiled by bulk RNA sequencing after ex vivo anti-PD-1 and polydatin treatment","description":"Tumor-infiltrating lymphocytes were recovered from six untreated head and neck squamous cell carcinoma surgical specimens and pooled. CD8+ TILs were sorted by flow cytometry into CD39-negative, CD39-medium and CD39-high populations and cultured for 72 h under four conditions: vehicle only, anti-PD-1 (nivolumab), polydatin (a G6PD inhibitor), and the combination of anti-PD-1 and polydatin. Bulk RNA sequencing of the twelve resulting libraries was used to determine how CD39 expression level stratifies the transcriptional response to combined checkpoint blockade and metabolic inhibition.","dates":{"publication":"2026/09/21"},"accession":"GSE345409","cross_references":{"GSM":["GSM10002838","GSM10002837","GSM10002836","GSM10002846","GSM10002835","GSM10002839","GSM10002841","GSM10002840","GSM10002845","GSM10002844","GSM10002843","GSM10002842"],"GPL":["34281"],"GSE":["345409"],"taxon":["Homo sapiens"]}}